NASDAQ:PBYIPuma Biotechnology Stock Price, Forecast & News

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PBYI stock has increased by 13.6% and is now trading at $10.53. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 4 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Puma Biotechnology.

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Puma Biotechnology.

Puma Biotechnology Inc (NASDAQ:PBYI) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.77) by $0.34. The biopharmaceutical company earned $51.20 million during the quarter, compared to analysts' expectations of $44.42 million. Puma Biotechnology had a negative net margin of 36.72% and a negative return on equity of 500.98%. The business's revenue for the quarter was down 48.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.21 EPS. View Puma Biotechnology's earnings history.

11 brokerages have issued twelve-month price objectives for Puma Biotechnology's shares. Their forecasts range from $6.00 to $17.00. On average, they expect Puma Biotechnology's share price to reach $12.22 in the next twelve months. This suggests a possible upside of 16.1% from the stock's current price. View analysts' price targets for Puma Biotechnology.

Media headlines about PBYI stock have trended negative on Sunday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Puma Biotechnology earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near future. View the latest news about Puma Biotechnology.

Puma Biotechnology saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 7,440,000 shares, a decline of 5.6% from the May 31st total of 7,880,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is presently 6.4 days. Currently, 22.4% of the company's stock are sold short. View Puma Biotechnology's Current Options Chain.

Some companies that are related to Puma Biotechnology include Zymeworks (ZYME), Ironwood Pharmaceuticals (IRWD), Zogenix (ZGNX), Intra-Cellular Therapies (ITCI), Epizyme (EPZM), Intercept Pharmaceuticals (ICPT), BELLUS Health (BLUSF), Mersana Therapeutics (MRSN), Cytokinetics (CYTK), MacroGenics (MGNX), Karyopharm Therapeutics (KPTI), Revance Therapeutics (RVNC), Akcea Therapeutics (AKCA), ZEALAND PHARMA/S (ZEAL) and Innoviva (INVA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Kite Pharma (KITE), Array Biopharma (ARRY), Freeport-McMoRan (FCX) and Celgene (CELG).

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBYI stock can currently be purchased for approximately $10.53.

Puma Biotechnology has a market capitalization of $414.46 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe.

The official website for Puma Biotechnology is www.pumabiotechnology.com.

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]